RARX - Ra Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
24.26
-0.74 (-2.96%)
As of 10:11AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close25.00
Open24.80
Bid24.67 x 800
Ask24.85 x 1300
Day's Range24.26 - 25.09
52 Week Range4.78 - 27.68
Volume49,251
Avg. Volume471,980
Market Cap1.021B
Beta (3Y Monthly)0.81
PE Ratio (TTM)N/A
EPS (TTM)-2.06
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est37.38
Trade prices are not sourced from all markets
  • Business Wire15 days ago

    Ra Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update

    Successful completion of Phase 2 trial of zilucoplan in generalized myasthenia gravis with rapid, clinically meaningful, and statistically significant reductions in QMG and M

  • Business Wire18 days ago

    Ra Pharmaceuticals to Present at the Cowen 39th Annual Health Care Conference

    Ra Pharmaceuticals, Inc. today announced that Doug Treco, Ph.D., President and Chief Executive Officer of Ra Pharma, will present at the Cowen 39th Annual Health Care Conference on Monday, March 11, 2019 at 1:30 p.m.

  • Business Wire22 days ago

    Ra Pharmaceuticals Supports 12th Annual Rare Disease Day® and Joins Global Movement to Raise Awareness for Rare Diseases

    Ra Pharmaceuticals, Inc. (RARX) today joins forces with 30 million healthcare advocates around the world for the 12th Annual Rare Disease Day®, an awareness day dedicated to elevating public understanding of rare diseases and calling attention to the special challenges people living with rare diseases face. “Despite important scientific advances in the treatment of rare diseases, there remains significant work to be done to help patients and families. At Ra Pharma, we are focused on developing medicines to treat patient populations with complement-mediated diseases and are committed to expanding patient access to more convenient life-saving medicines,” said Doug Treco, Ph.D., President and Chief Executive Officer of Ra Pharma.

  • InvestorPlace25 days ago

    5 Clinical-Stage Biotech Stocks to Buy

    Last year was not kind to many biotech stocks. When investors abandoned high growth equities as the economy and market got rocky, biotech stocks were some of the first to go. This was especially true for many of the clinical-stage drug developers with no actually marketed products under their belts. The equal-weighted SPDR S&P Biotech (NYSEArca:XBI) -- which has a high concentration of smaller biotech stocks -- managed to lose around 24% in 2018.Investors clearly were not willing to gamble on those smaller stocks that don't have revenues.But the new year is shaping to be a bit better for biotech stocks in general and those clinical-stage developers. So far, risk has once again returned to the menu and the effects of the government shutdown on the FDA are no longer an issue. Investors have once again taken a shine to early-stage drug developers. The XBI is up more than 16% year-to-date.InvestorPlace - Stock Market News, Stock Advice & Trading TipsAnd more gains could be in store for the clinical biotech stocks. * 7 Cheap Stocks That Make the Grade Even better is that, prices for many of the earlier developers remain below their peaks. This gives investors plenty of chances to snag-up some promising drug firms with some serious potential under their belts. But which ones to buy? Here are five clinical stage biotech stocks to buy today. Nightstar Therapeutics (NITE)One of the hottest trends in biotech stocks is gene therapy. There are thousands of diseases and disorders are caused by faulty genes. In a nutshell, gene therapy is fixing those problems by either adding new genes to fight faulty ones, replacing/editing missing/broken genes or actually "turning off" the genes causing problems. It's a major breakthrough and is just starting to get critical mass with the FDA and drug makers.On the ground floor of that is Nightstar Therapeutics (NASDAQ:NITE). NITE's main focus is on gene therapies for patients who suffer from rare inherited retinal diseases that would otherwise progress to blindness. The biotech has several candidates in various trials. It's lead product targeting a condition called choroideremia begun enrolling for phase 3 trials. Choroideremia is a rare disease that has no current treatments. Data so far for NITE's work here has been more than promising and has received several fast-track FDA designations based on early data.But NITE isn't done yet.The clinical stage biotech stock's work on X-Linked Retinitis Pigmentosa -- another genetic eye disease -- has proven successful as well. Nightstar was successful in its "proof of concept" during the fall of last year. Phase 2/3 data is expected in mid-2019.Both of these as well as NITE's full pipeline of other therapies could be very fruitful for investors over the next few years. And that makes the biotech stock a big buy. Ra Pharmaceuticals Inc. (RARX)Clinical biotech stocks can win if they are able to offer something better than established treatments. That's exactly Ra Pharmaceuticals' (NASDAQ:RARX) bag.Generalized Myasthenia Gravis (gMG) is a serious condition that progressively weakens muscles. It's rare and only around 60,000 Americans suffer from the disorder. The only drug approved to treat is the insanely priced Soliris. Soliris and its hefty price tag have allowed Alexion Pharmaceuticals (NASDAQ:ALXN) to reap billions in revenues. But that might end if RARX has its way.At the end of last year, RARX's lead therapy zilucoplan posted amazing phase 2 results for gMG. Digging into the data, Ra's drug was able to improve patients' quantitative MG scores by 6 points. Soliris was approved after improving patients scores by just 4.6 points. Now, that Soliris improvement was at a much great rate than those receiving a placebo, RA wasn't too far behind. What it really means is that RARX should be able to meet with the FDA to discuss the design of a phase 3 trial and work towards getting the drug approved.With a strong balance sheet and continued insider stock purchases, Ra Pharmaceuticals has plenty of potential to pay for that trial and actually see it to the end. * 5 Dow Jones Stocks That Will Lead the Market Higher For investors, with blockbuster replacement looming, RARX stock is alone biotech that shouldn't' be missed. Aurinia Pharmaceuticals (AUPH)Clinical stage biotech stocks tend to be gambles. That's sort of the situation with Aurinia Pharmaceuticals (NASDAQ:AUPH). A ton hinges on a late-stage trial reporting at the end of the year. However, it's a gamble that may be worth looking at.For AUPH, the mission remains to tackle lupus. Lupus remains one of the least understood auto-immune diseases. With lupus, the body's immune system mistakenly attacks healthy tissue. That's pretty bad by itself, however, many people often develop lupus nephritis (LN) and succumb to life-threatening kidney damage. Aurinia is developing a compound called voclosporin works by inhibiting an enzyme that activates immune cells. Voclosporin worked amazingly in phase 2 trials and had a high rate of success for LN patients.Aurinia should wrap phase 3 trials for the drug and LN treatments at the end of 2019. If it hits, analysts now peg sales of the medicine to fetch around $1 billion annually. Naturally, investors have placed a lot of stock on the drug and AUPH's potential. If it hits, investors could be looking at huge blockbuster and a sharp increase in AUPH stock.And if it doesn't, Aurinia may be ok as the firm is developing voclosporin for various indications as well. But given the potential, the firm may be one of the best clinical biotech stocks to buy for a gamble. Arena Pharmaceuticals (ARNA)Partnerships can mean big things for clinical stage biotech stocks. A prime example is Arena Pharmaceuticals (NASDAQ:ARNA).For starters, ARNA has a rich pipeline of treatments in mid-to-late stages of trials. This includes drugs for Ulcerative Colitis, Crohn's Disease, and IBS. That alone is worth the price of admission. But where Arena could be winning is in its drug Ralinepag. Ralinepag has been touted as potentially a best-in-class medicine for treating pulmonary arterial hypertension. So, naturally, any biotech firm that has drugs already on the market that could be threatened by the future blockbuster is willing to bend over backward to defend their position.And that's just United Therapeutics (NASDAQ:UTHR) did by paying Arena $800 million cash up-front as well as up to $400 million in milestone payments and double-digit royalties on sales in order to license Ralinepag.For Arena, this is a win-win. They get cash to develop it and other drugs in their platform and still are able to share in the long-term success of the drug. For investors, this is a big win as well and shows that ARNA's management is thinking about the total portfolio and not just one drug. * 5 Big-Yield REITs to Check Out Now In the end, Arena should have enough money to make its pipeline a reality and get more of its drugs out to market. That makes the clinical biotech stock one to bet on. Galapagos (GLPG)When it comes to late-stage biotech stocks or really any drug manufacturer, pipeline means everything. It's what drives your valuation and future potential. Luckily for clinical-stage firm Galapagos (NASDAQ:GLPG), its pipeline is very robust indeed. GLPG has multiple late-stage programs as well as 25 different drugs in discovery/early trial stages. But what separates Galapagos is that that pipeline is actually churning out real results.Partnering with biotech-giant Gilead (NASDAQ:GILD), GLPG's Filgotinib is quickly becoming a winner and after impressive phase-3 data, the duo has moved closer to marketing the drug rheumatoid arthritis. At the same time, Galapagos has scored wins in cystic fibrosis, idiopathic pulmonary fibrosis, systemic sclerosis and a fast-track designation for its osteoarthritis treatment.All in all, GLPG has many shots on goal to make it. That's very important to a clinical-stage biotech stock. And yet, last years rout of the sector sent shares of GLPG downwards and they've stayed that way. Today, Galapagos is still about 17% below its 2018 peak of $117 per share.Given its huge pipeline -- that is increasingly winning in trials -- that difference may not last long. When it comes to clinical stage biotech stocks, GLPG is one you must own.Disclosure: At the time of writing, Aaron Levitt was Long the iShares Nasdaq Biotechnology ETF -- which holds a position in GILD, ALXN, AUPH, GLPG, RARX, UTHR and ARNACompare Brokers The post 5 Clinical-Stage Biotech Stocks to Buy appeared first on InvestorPlace.

  • Business Wire29 days ago

    Ra Pharmaceuticals to Present at the 8th Annual SVB Leerink Global Healthcare Conference

    Ra Pharmaceuticals, Inc. today announced that Ramin Farzaneh-Far, M.D., Chief Medical Officer of Ra Pharma, will present at the 8th Annual SVB Leerink Global Healthcare Conference on Thursday, February 28, 2019 at 2:30 p.m.

  • Hedge Funds Are Betting On Ra Pharmaceuticals, Inc. (RARX)
    Insider Monkey3 months ago

    Hedge Funds Are Betting On Ra Pharmaceuticals, Inc. (RARX)

    Before we spend days researching a stock idea we’d like to take a look at how hedge funds and billionaire investors recently traded that stock. S&P 500 Index ETF (SPY) lost 8.7% through October 26th. Forty percent of the S&P 500 constituents were down more than 10%. The average return of a randomly picked stock […]

  • Business Wire3 months ago

    Ra Pharmaceuticals Announces Pricing of Public Offering of Common Stock

    Ra Pharmaceuticals, Inc. (RARX) (“Ra Pharma”) today announced the pricing of an underwritten public offering of 8,387,097 shares of its common stock, at a public offering price of $15.50 per share, before underwriting discounts and commissions. Ra Pharma also granted the underwriters a 30-day option to purchase up to an additional 1,258,064 shares of its common stock. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $130.0 million, excluding any exercise of the underwriters' option to purchase additional shares.

  • Benzinga3 months ago

    The Daily Biotech Pulse: Management Change At Merck, Jazz Buyback, Arrowhead Earnings

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Dec. 10) Homology Medicines Inc (NASDAQ: FIXX ) OvaScience Inc ...

  • Why Nutrisystem, Xperi, and Ra Pharmaceuticals Jumped Today
    Motley Fool3 months ago

    Why Nutrisystem, Xperi, and Ra Pharmaceuticals Jumped Today

    Find out which of these stocks got a buyout bid.

  • Business Wire3 months ago

    Ra Pharmaceuticals Announces Proposed Public Offering of Common Stock

    Ra Pharmaceuticals, Inc. (RARX) (“Ra Pharma”) today announced that it intends to offer and sell, subject to market and other conditions, $100 million of its common stock in an underwritten public offering. Ra Pharma expects to grant the underwriters a 30-day option to purchase up to $15 million of additional shares of its common stock. Jefferies, BMO Capital Markets, and Stifel are acting as joint book-running managers for the offering.

  • Here's Why Ra Pharmaceuticals Inc. Is Soaring Today
    Motley Fool3 months ago

    Here's Why Ra Pharmaceuticals Inc. Is Soaring Today

    Investors are cheering for successful results from a mid-stage trial with the company's lead candidate.

  • Benzinga3 months ago

    Ra Pharma Shares Rally: What You Need To Know

    Ra Pharmaceuticals Inc (NASDAQ: RARX ) shares are surging higher Monday morning, reacting to an announcement by the company concerning clinical trial results of its autoimmune disorder drug. What Happened ...

  • Business Wire3 months ago

    Ra Pharmaceuticals Announces Positive Top-line Data from Phase 2 Trial of Zilucoplan in Patients with Generalized Myasthenia Gravis

    Ra Pharmaceuticals, Inc. (RARX) today announced positive top-line results from the Company’s Phase 2 clinical trial evaluating zilucoplan for the treatment of generalized myasthenia gravis (gMG), achieving clinically meaningful and statistically significant reductions in both the primary and key secondary endpoints for both zilucoplan dose groups tested versus placebo at 12 weeks.

  • Business Wire3 months ago

    Ra Pharmaceuticals Receives Development Milestone Payment Under Agreement with Merck

    Ra Pharmaceuticals, Inc. (RARX) today announced that it has received a development milestone payment under its collaboration agreement with Merck, known as MSD outside the US and Canada. The milestone payment is associated with the companies’ collaboration for a non-complement cardiovascular target with a large market opportunity. Initiated in 2013, this collaboration leverages Ra Pharma’s Extreme Diversity™ platform aimed at producing macrocyclic peptides that have the diversity and specificity of antibodies, while retaining the pharmacologic attributes of small molecules.

  • Business Wire4 months ago

    Ra Pharmaceuticals Elects Bo Cumbo to Board of Directors

    Ra Pharmaceuticals, Inc. (RARX) today announced the election of Bo Cumbo to its board of directors. Mr. Cumbo is a veteran of the biotechnology industry and has played strategically important roles in the successful launch of 11 products across multiple organizations and therapeutic categories, including rare neuromuscular diseases, hepatitis, HIV, and cardiovascular disease. “In his more than twenty-year career in the biotechnology and pharmaceutical sectors, Bo has played an integral role in the planning and implementation of numerous, highly successful and industry-leading commercial product launches,” said Doug Treco, PhD, President and Chief Executive Officer of Ra Pharma.

  • Business Wire4 months ago

    ADDING and REPLACING Ra Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update

    Dosing completed in Phase 2 trial of zilucoplan in generalized myasthenia gravis

  • Business Wire4 months ago

    Ra Pharmaceuticals to Present at Upcoming Investor Conferences

    Ra Pharmaceuticals, Inc. today announced that senior management will present at the following upcoming investor conferences:

  • Can the Rally in Ra Pharmaceuticals (RARX) Shares Continue?
    Zacks6 months ago

    Can the Rally in Ra Pharmaceuticals (RARX) Shares Continue?

    Ra Pharmaceuticals, Inc. (RARX) has been on the move lately as the stock has risen by 60.8% in the past four weeks, and it is currently trading well above its 20-Day SMA.

  • Ra Pharma Announces Positive Results from Phase 1b Pharmacokinetic Study of Zilucoplan (RA101495 SC) in Patients with Renal Impairment
    Business Wire6 months ago

    Ra Pharma Announces Positive Results from Phase 1b Pharmacokinetic Study of Zilucoplan (RA101495 SC) in Patients with Renal Impairment

    Ra Pharmaceuticals, Inc. (RARX) today announced positive results from the Company’s Phase 1b pharmacokinetic (PK) study evaluating zilucoplan (RA101495 SC) in patients with renal impairment. The Company has received International Nonproprietary Names (INN) clearance for use of the name zilucoplan from the World Health Organization. The Phase 1b, multi-center, open-label trial was designed to evaluate the PK profile of zilucoplan in patients with severe renal impairment as a lead-in to studying zilucoplan in complement-mediated renal disorders.

  • Business Wire6 months ago

    Ra Pharmaceuticals to Present at the 2018 Cantor Global Healthcare Conference

    Ra Pharmaceuticals, Inc. today announced that Doug Treco, PhD, President and Chief Executive Officer of Ra Pharma, will present at the 2018 Cantor Global Healthcare Conference on Tuesday, October 2, 2018 at 9:10 a.m.

  • Business Wire6 months ago

    Ra Pharma Elects Aoife M. Brennan, M.B., B.Ch., to Board of Directors

    Ra Pharmaceuticals, Inc. (RARX) today announced the election of Aoife M. Brennan, M.B., B.Ch., to its board of directors. “Dr. Brennan has an impressive track record of success in advancing the development of numerous drug candidates throughout her career, with experience in the fields of rare disease, hematology, and neurology, among other key therapeutic areas,” said Doug Treco, PhD, President and Chief Executive Officer of Ra Pharma. Dr. Brennan joined Synlogic in 2016 from Biogen, where she most recently served as Vice President and Head of the Rare Disease Innovation Unit, which included programs ranging from pre-clinical to commercial.

  • Business Wire7 months ago

    Ra Pharma Announces Completion of End-of-Phase 2 Interactions with FDA and Design of Phase 3 PNH Program

    Ra Pharmaceuticals, Inc. (RARX) today announced the completion of End-of-Phase 2 interactions with the U.S. Food and Drug Administration (FDA) for its global Phase 3 program of RA101495 SC for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Based on feedback provided by FDA during End-of-Phase 2 discussions regarding the Company’s planned global Phase 3 PNH program, as well as advice previously provided by the Medicines and Healthcare products Regulatory Agency in the United Kingdom (MHRA) and Health Canada, Ra Pharma plans to initiate a global, pivotal, single-arm Phase 3 trial to evaluate the safety and efficacy of RA101495 SC in approximately 40 treatment-naïve PNH patients.

  • Business Wire7 months ago

    Ra Pharmaceuticals Reports Second Quarter 2018 Financial Results and Announces Early Completion of Enrollment in gMG Phase 2 Program

    Surpassed target enrollment in Phase 2 trial of RA101495 SC for gMG

  • Business Wire9 months ago

    Ra Pharmaceuticals Presents Data on Oral, Small Molecule Complement Inhibitors and Phase 2 RA101495 SC Program in PNH at the 23rd Congress of the European Hematology Association

    Ra Pharmaceuticals, Inc. today announced the presentation of scientific data at the 23rd Congress of the European Hematology Association , June 14-17, 2018 in Stockholm, Sweden.